Association of vancomycin or teicoplanin gram-positive prophylaxis with infection profile and mortality in ECMO patients: A real-world cohort study

Prophylactic use of vancomycin or teicoplanin in ECMO patients was associated with lower in-hospital mortality without a statistically significant reduction in overall infection rates. These findings represent associations among patients surviving beyond the early ECMO period and should not be interpreted as causal. The higher use of subsequent Gram-negative antibiotics underscores the need to balance potential benefits against antimicrobial resistance. Further prospective studies are warranted to clarify the role of prophylactic antibiotic strategies in this population.